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Introduction and background: In the last few years, a substantial body of evidence indicates that cutaneous psori-
asis and psoriatic arthritis patients are at higher risk of developing cardiovascular disease. However, underlying
mechanism remains not completely understood. In this reviewwe discuss the role of the immune system in the
development of atherosclerosis, focusing on available data implicating the role of an enhanced immune-
mediated proinﬂammatory status in psoriasis and psoriatic arthritis diseases.
Methods: A systematic search was performed on Pubmed until November 2014, with preference to the sources
published within the past 8 years, including epidemiological studies (prospective and retrospective); cross-
sectional case–control studies and reviews. Articleswere selected according critical associations using the follow-
ing keywords: arthritis, immune-mediated inﬂammatory diseases, and psoriasis. These were combined with
closely related keywords reﬂecting cardiovascular diseases: atherogenesis, endothelial dysfunction, intima
media thickness, subclinical atherosclerosis, plaque, thrombosis, thrombus, ﬁbrinolysis, coagulation, and reactive
oxygen species. Both types of disease selected termswere separately combinedwith non-traditional (innate and
adaptive pro and anti-inﬂammatory immune molecules and cells) and traditional (metabolic related conditions
and molecules) cardiovascular risk factors.
Results and conclusions: Psoriasis and psoriatic arthritis diseases illustrate that immune-mediated activated cross-
roads of inﬂammation beyond enhanced cardiovascular risk factors are the result of an interplay between differ-
ent proatherogenic mediators derived from metabolic, vascular and autoimmune joint and skin inﬂamed target
tissue. Consistent with this point of view, psoriasis and psoriatic arthritis diseases offer an invaluable opportunity
to reinforce our knowledge about atherosclerotic cardiovascular disease.© 2015 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
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One hundred years ago, Nikolai N. Anichkov demonstrated that cho-
lesterol alone by consumption of fat was able to produce lesions and
atheromatous changes in the vascular wall [1]. He also described the
presence of inﬂammatory cells in the lesion, but these ﬁndings
remained forgotten for many decades. In 1995, Hansson and others
established that atherosclerosis has many features of a chronic inﬂam-
matory process, giving rise to the immune-mediated hypothesis behind
atherogenesis [2]. However, the interest among cardiologists and in pre-
ventivemedicine at that timewas limited. Nowadays, the importance of
such discoveries can be critically valued in immune-mediated inﬂam-
matory disorders (IMID) in general but more critically in psoriasis (Ps)
and psoriatic arthritis (PsA). It is known that both, adaptive and innate
immunity, participate in every step of atherogenesis and associated car-
diovascular risk (CVR) factors. In fact, these diseases seem to increase
CVR using both traditional and non-traditional CVR factors [3], offering
a comprehensive basis to explain the immune-mediated nature of ath-
erogenesis beyond autoimmune condition, outlining the different cross-
roads of inﬂammation.
2. Psoriasis and psoriatic arthritis
Psoriasis (Ps) and psoriatic arthritis (PsA) belong to the family of
IMID, affecting predominantly the skin and joints. The prevalence of
Ps varies between 2% and 3% [4] worldwide with a similar distribution
among male and female. Epidemiological studies show a peak in inci-
dence between the second and third decades in life [5]. It has been esti-
mated that 7–42% of Ps patients develop an inﬂammatory arthropathy,
usually manifesting as a mono or asymmetrical oligo-arthritis [6]. Sub-
stantial body of evidence suggests that PsA patients are at higher risk
of developing atherosclerotic cardiovascular disease (CVD) [7–9] and
mortality [10,11]. To date, the pathogenesis of Ps and PsA remains
unknown. Autoantigens have not been identiﬁed and the speciﬁcity of
inﬁltrating lymphocytes is still unknown. Several suspected environ-
mental triggers and poorly characterized factors (e.g. infections, drugs,
physical and emotional stress) have been implicated in the initial course
of these diseases, most likely against a genetically predisposed back-
ground [9]. Nowadays, Ps is considered an immune-mediated skin dis-
ease, and PsA regarded as a seronegative (rheumatoid factor negative)
arthritis. In Ps and PsA, the inﬂammatory features/responses in skin
and joints are very similar, including the composition of inﬂammatory
inﬁltrates, and vascular changes [12]. Moreover, the cellular inﬁltrate
is predominantly perivascular [13].
The contribution of B lymphocytes to the pathogenesis is poorly un-
derstood. However, none of the forms of Ps or PsA have been associated
with serum auto-antibodies. In contrast, T lymphocytes are the most
abundant in both skin and the synovial ﬂuid of joints, where the domi-
nant subpopulations include Tc1 (subpopulation of CD8+ cytotoxic T
cells that secrete IFN and IL-4) aswell as T-helper 1 lymphocyte subpop-
ulation (Th1) and Th17 (IL17+T-helper cells)which interact with den-
dritic cells, macrophages and target tissue cells. These cells are attractedamong other molecules by elevated concentrations of MCP-1 as was
found in synovial ﬂuid [14] and skin biopsies obtained from Ps and
PsA patients [15]. Their role in the pathogenesis will be discussed in
more detail below.
3. Atherosclerosis
Atherosclerosis is a complex low inﬂammatory disease character-
ized by derangements in the metabolic and immune system homeosta-
sis that lead to pathogenic chronic progressive vascular damage.
Classical knowledge distinguishes between inﬂammatory and non-
inﬂammatory diseases. However, this distinction is no longer appropri-
ate because the identiﬁcation of inﬂammatory mechanisms is associat-
ed with the traditionally called “non-inﬂammatory diseases”.
Although atherogenesis belonged to this group during several decades,
now it is well known that the immune system acts on the endothelial
wall and triggers an inﬂammatory cascade, leading to a progressive
low-grade inﬂammatory process of the arterial vascular wall in re-
sponse to accumulation and oxidation of lipoproteins. In addition the
immune system is critically involved in the production of atherosclero-
sis plaque containing macrophages, lymphocytes and other immune
cells [16].
Studies in hypercholesterolemia induced immune activation in
mouse models of atherosclerosis highlight the critical balance between
Th1 cells [17] and Treg [18]. Inﬂammation in the arterial intima seems to
be related with protective and pathogenic immune responses against
modiﬁed self-antigens in the atherosclerotic plaque.
The paradigm of atherosclerosis as an inﬂammatory disease is
widely accepted, although little is known about its association with
rheumatic diseases, particularly the underlying mechanisms. Chronic
inﬂammatory systemic diseases could share common immune-mediat-
ed inﬂammatory pathways. Molecules and immune cells derived from
both diseases may interact together in promoting a pathogenic effect.
Despite differing initial events between the above-mentioned diseases
that could exist, increasing evidence indicates that even in clinically het-
erogeneous diseases both of them could share common immunological
pathways that may damage the CV system. The contribution of the
chronic inﬂammatory state to the CVR, has mainly been investigated
in the prototypical inﬂammatory disorder, i.e. rheumatoid arthritis
(RA) [19–21].
Consistent with these studies, the chronic activation of innate and
adaptive inﬂammatory pathways, which are described below, is be-
lieved to accelerate or trigger critical atherosclerosis events in Ps and
PsA, including atherosclerotic plaque progression, destabilization, and
ultimately rupture, with subsequent clinical sequelae like myocardial
infarction (MI) or stroke.
Identifying critical inﬂammatory pathways involved in progression
and destabilization of pre-existing atherosclerotic plaques may help to
deﬁne novel therapeutic strategies to further reduce CVD burden, par-
ticularly in patients with chronic inﬂammatory disorders. Based on pre-
vious papers, a multidisciplinary expert committee was designated a
few years ago in accordance with EULAR (European League against
Table 1
Representative summary of epidemiological studies (prospective and retrospective)
linking PsA to associated cardiovascular risk and comorbidities (RCM), published between
2006 and 2014. AC: alcohol consumption; BMI: body mass index; CAD: coronary artery
disease; CCF: controlled for confounding factors; CHF: congestive heart failure; GP: gener-
al population; CVD: cardiovascular disease; DM: diabetes mellitus; DMARDS: disease-
modifying antirheumatic drugs; ED: endothelial dysfunction; GR: gender: GP: general
population; HDL: high-density lipoprotein; HL: hyperlipidemia; HTN: hypertension;
ICAM-1: intercellular adhesion molecule 1; IHD: ischemic heart disease; IL6: interleukin
6; LDL: low density lipoprotein Lp(a): lipoprotein A;MI:myocardial infarction; OB: obesi-
ty; PVD: peripheral vascular disease; TC: total cholesterol; TG: triglycerides; TRF: tradi-
tional risk factors; VLDL: very low density lipoprotein.
Author/year Number of patients & study
proﬁle
Findings
Han, 2006 3066 PsA patients vs
clinically asymptomatic
controls matched by age, sex,
geographic region
Higher prevalence for CHF,
PVD, IHD atherosclerosis,
type II diabetes, HL, and HTN
in PsA patients than controls
Sattar, 2007 127 patients with active
Ps/PsA after at least ﬁrst
failure with DMARDS
treatment, onset of disease
after 16 years old, PsA of
more than 6 month duration
with active arthritis in 3 or 4
swollen joints. Double–blind
placebo (n = 42) controlled
study performed with two
doses of Onercept 100 (n =
42) and 50 mg (n = 43) for
12 weeks.
Result compared against
baseline before and after the
end of treatment with
Onercept. Results indicate
higher CRP, that positively
correlate with Lp(a);
ICAM-1; IL6; homocysteine;
same levels Apo-I¸ Apo-B &
TG
Gonzalez-Juanatey,
2007
59 PsA patients vs. 59 control
patients
Without clinically evident
CVD adjusted for age and
ethnic.
Carotid artery IMT correlated
with age, time of PsA
diagnosis, disease duration,
total cholesterol & LDL
Eder, 2008 40 PsA patients compared
with 40 controls matched by
age, sex, and CVR factors.
Higher IMT among PsA
patients. Multivariate
analysis demonstrated that
PsA status, age & TG levels
were associated with the
presence of carotid plaque.
TRF prevalence was higher
among PsA patients.
Tam, 2008 102 PsA patients from
Southern China.
Increased prevalence of DM
and HTN was found in PsA
group compared with age-
and sex-matched controls,
even after adjusting for the
BMI.
Kimhi, 2009 Carotid artery IMT from 47
patients with PsA were
compared with 43 healthy
controls matched for age and
sex.
The average IMT (mean/SD)
in PsA patients was
signiﬁcantly compared to GP
even after adjustment for
age, GR, BMI, HTN&HL.
Gladman 2009 648 patients with Ps and PsA CV risk. Severity of skin
involvement is an
independent CVR factor
Shang, 2011 94 PsA patients without
clinical evidence of CVD and
63 healthy subjects.
PsA patients without
established CVD & in the
absence of TRF have a high
prevalence of subclinical ED
via echocardiography and
imaging studies.
Eder, 2013 Cross-sectional study
comparing 125 PsA with 114
Ps patients.
Study suggests that PsA
patients suffer from more
severe subclinical
atherosclerosis compared
with Ps patients,
independent of TRF &
correlates with inﬂammatory
markers.
Ogdie, 2014 Longitudinal cohort study
comparing 8706 PsA, 41,752
RA, 138,424 Ps and 82,258
controls
Patients with RA and Ps have
increased mortality
compared with the GP but
patients with PsA do not have
a signiﬁcantly risk of
mortality.
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make recommendations for the management of RA and other forms of
inﬂammatory arthritis. Apart from the management of conventional
risk factors, this committee suggests an aggressive inﬂammation sup-
pressive therapy to further reduce CVR [22].
Emerging evidence supports the hypothesis that cardiovascular
morbidity and mortality in Ps and PsA are increased in comparison to
the general population being the leading causes of death in PsA [23].
On other hand, CVD is increasingly considered an extra-articular mani-
festation in Ps patients, with the chronic inﬂammatory state as a poten-
tial driving force behind the accelerated atherogenesis [24]. In this
direction few papers have been published related to CVR factors [7,8,
25] which are shown in Table 1. Some representative prospective and
retrospective epidemiological surveys, published between 2006 and
2014 (Table 1) indicate that Ps and PsA patients, as compared to normal
controls, exhibit an increased prevalence of MI, ischemic heart disease,
hypertension, diabetes and dyslipidemia.
Although multiple CVR factors are associated with Ps, key compo-
nents of the metabolic syndrome are more strongly connected with
more severe PsC [26] Recent studies [27] also indicate an increase in in-
ﬂammatory burden in PsA compared to Ps (Table 1). In contrast the risk
of developing a CV outcome (MI, ischemic stroke and transient ischemic
attack), was not elevated in early Ps patients in a matched follow-up
study case–control analysis [28,29].
4. Inﬂammatory and classical cardiovascular risk factors
4.1. Inﬂammatory risk factors
Accelerated atherogenesis in Ps and PsA may involve multiple
inﬂammation-related and non-inﬂammatory factors. Since a substantial
amount of data accumulate in the past of this issue we provide a brief
insight into the most common mechanisms involved.
As previously mentioned, Ps and atherosclerosis have a similar im-
mune innate and adaptive pathogenic proﬁle. Both share a similar histo-
logical hallmark involving activated lymphocytes (Th1⁄Th17cells),
proinﬂammatory cytokines and inﬂammatory cells, including skin,
joint-tissue and endothelial wall macrophages [30] (See Figs. 1 and 2
for more details).
4.1.1. Innate immunity
Toll-like receptor 2 (TLR-2) and toll-like receptor 4 (TLR-4) trigger
receptor-mediated events, including cytokine-mediated inﬂammation,
which are involved in atherosclerosis [31], Ps and other pathologies
[32]. TLR expression is positively correlated with plasma tumor necrosis
alpha (TNF-α) levels [33]. Cytokine-triggered TLRs activation is known
to modulate major pathological processes, including inﬂammation,
angiogenesis, tissue remodeling, and ﬁbrosis. Although joints are the
most obvious inﬂammation sites in PsA, proinﬂammatory cytokines,
most likely TNF-α and interleukin 6 (IL-6), are released in blood circula-
tion and act on distant organs (immune system, adipose tissue, liver,
hematopoietic tissue, skeletal muscle, glands, and endothelium). These
effects are linked to systemic inﬂammation and lead to a proatherogenic
proﬁle. Cytokines orchestrate endothelial adhesiveness, matrix metallo-
proteinases (MMPs) activation, reactive oxygen species (ROS) produc-
tion, CRP, ﬁbrinogen, and plasminogen activator inhibitor-1 (PAI-1)
release [34].
Indeed, atherogenic lipid alterations, oxidative stress abnormalities,
vascular injury repair failure, arterial stiffness, insulin resistance induc-
tion, endothelial dysfunction, hypercoagulable state, homocysteine eleva-
tion, and pathogenic T cell up-regulation could all be attributed in part to
the proinﬂammatory actions of cytokines. Common inﬂammatory mech-
anisms in PsA and atherosclerosis may be related to other factors by the
high number of overlapping molecules, including cytokines [interleukins
(IL-2, IL-6, IL-15, IL-17, IL-18, IL-20, IL-23)], interferon alpha (IFN-α),
Oncostatin M, (TNF-α), chemokines (Fractalkine, growth-regulated
Fig. 1. Immunopathogenesis of Ps & PsA associated events that worsen the cardiovascular risk proﬁle. Chronic inﬂammation of the skin and joints havemany common immunopatholog-
ical features, including genetic predisposition, composition of inﬂammatory inﬁltrates, vascular changes, early immune events and proangiogenic similarities. The cellular inﬁltrate is pre-
dominantly perivascular (1). B lymphocytes are abundant but the contribution of B cells to the pathogenesis is unlikely (2). T lymphocytes are the most abundant in both skin and joints,
where thedominant types are cytotoxic T lymphocyte CTL, Th1 and Th17 (3).Neuropeptides (NP) are also involved inproinﬂammatory pathways (4). Antigen is presented to naive CD4 Th
cells during immune synapse (5) in the lymph node. Emerging lymphocytes migrate preferentially to skin and joints, where the above-mentioned inﬁltrating T lymphocytes (CD4, CD8)
interact with local APC (Langerhans cells, myeloid-DC and plasmacytoid-DC) to produce chronic inﬂammatory conditions. Local re-activated T cells (6) secrete chemokines and cytokines
that amplify the inﬂammatory environment, resulting in the formation of psoriatic plaque, induction of degradation of cartilage and perhaps atherosclerotic plaque. Since the suppressive
activity of regulatory cells is decreased in both tissue and blood, lymphocytes show high replicative power. The chronic production of proinﬂammatory cytokines (IFNγ, TNFα) crucially
contributes to the perpetuation of the disease (7). TNFα is critically involved in induction of inﬂammatory degradation of cartilage and bone (8). The osteolytic activity (9) is the result of
the activation of osteoclasts by the action of IFNγ. APC: antigen-presenting cell; aOC: activated osteoclast; DC: dendritic cells;MDC:mature DC; IDC: immature DC; CRP: C reactive protein;
OPG: osteoprotegerin; MHC: major histocompatibility complex; MMP: metalloproteinases; RANKL: receptor activator of Nuclear Factor-Kappa B Ligand; VEGF: vascular endothelial
growth factor; B7L: family of structurally related ligands, which bind to APC counter-receptor (B7).
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10), IL-8, MCP-1, monokine induced by interferon gamma (MIG/CXCL9),
adipokines (Resistin, Leptin, PAI-1), adhesion molecules (ICAM ⁄LFA-1
(leukocyte function-associated antigen-1),⁄CD154 (OX40L)/CD134
(OX40), co-stimulatory molecules (CD80, CD28, CD40⁄CD40L), lympho-
cyte proﬁle (Th1⁄Th17up-regulation, Treg down-regulation, CTL effector
activity), NK cells, Natural killer T (NKT) cells, myeloid dendritic cells,
plasmacytoid dendritic cells, monocytes⁄macrophages, mast cells and
neutrophils), complement activation [35], TLR-mediated inﬂammation
(TLR-2, TLR-4, TLR-9) [28–30], and other important factors (CRP,
endothelin-1, inducible nitric oxide synthase (iNOS), heat shock protein
(HSP60, HSP65, HSP70), matrix metalloproteinases (MMP-2, MMP-9),
and oxidized low density lipoprotein (LDL)) [36–38]. Some molecules
listed before and other PsA-related serum cytokine patterns have been
demonstrated bymultiplex cytokine array systems in Norwegian PsA pa-
tients [39]. In the same study cytokine serum proﬁle in PsA patients indi-
cates that IL-10, IL-13, IFN-α, epidermal growth factor (EGF), vascular
endothelial growth factor (VEGF), ﬁbroblast growth factors (FGF), CCL-3
(MIP-1α), CCL-4 (MIP-1α), CCL-11 (Eotaxin) and GCSF are increased.
Few of these cytokines previouslymentioned [40,41] and their pathogen-
ic contribution at different stages in the pathobiology of atherothrombosis
andPsA are not clear yet [34]. NK cells possess both inhibitory and activat-
ing killer immunoglobulin-like receptors (KIRs). Activated KIRs (KIR2DS-
1 and KIR2DS-2) increase the susceptibility to PsA [42]. In addition, NKcells are found in the inﬂammatory inﬁltrate in psoriatic skin
lesions. Although more studies must be done, emerging evidence sup-
ports a role for NK cells in Ps. Inverse correlation exists between the pre-
dominant CD56–/CD16+ Lo NK cell population and body mass index.
Therefore, adipose immune cell phenotype and function, may provide
greater insight into cardio-metabolic pathophysiology in psoriasis [43].
One of the natural killer group 2 member D (NKG2D) ligands in
human is the MHC class-I chain-related molecule A (MICA). MICA is
usually absent on normal cells, but its expression rises upon cellular
stress on target cells such as endothelial cells. Xia et al. reported that im-
mune activation resulting from NKG2D–ligand interaction promotes
atherosclerosis [44].
NKT cells, are a heterogeneous subset of T cell lineage lymphocytes
that bear NK cell molecules and T cell receptors, which recognizemicro-
bial glycolipids and their own endogenousmammalian lipids presented
by the MHC I-like molecule (CD1d) and have been implicated in the
pathogenesis of various autoimmune diseases including Ps. Due to the
numerous functions of NKT cells that link innate and adaptive immuni-
ty, their role in Ps is complex and still elusive. ApoE and LDL receptors
have been involved in antigen uptake for presentation to NKT cells
[45]. Controlling the activation state of NKT cellsmay represent a poten-
tial new therapy for atherosclerosis [46].
Our knowledge of biologically active serum molecules and cells in-
volved in the pathogenesis of both PsA and atherosclerosis is still not
Fig. 2. Schematic of early and late immune-mediated events implicated in atherosclerosis. (A) LDL from blood is modiﬁed by enzymes and oxygen radicals to form oxidized LDL (oxLDL)
(1). Biologically active lipids induce endothelial cells (EC) to express leukocyte adhesion molecules (2), leading to early monocytes (3) and later T cells (4) entrance into inﬂamed tissue.
Monocytes differentiate into macrophages (5) in response to local macrophage colony-stimulating factor (M-CSF) and others stimuli. Expression of many pattern-recognition receptors
increases, including scavenger receptors (SR) and Toll-like receptors (TLRs). Macrophage, active ingest oxLDL particles without a regulated pattern, leading to intracellular cholesterol ac-
cumulation and the formation of foam cells. TLRs bindoxLDL (6), which in turn triggers theproduction ofmany proinﬂammatorymolecules bymacrophages. (B) Antigenpresentation and
Th-cell activation and differentiation occur in regional lymph nodes. Antigen involved in immune synapsis presentation is unknown, but the speciﬁcity of effector cells recognizes oxLDL
and HSP60. (7) Lymph node emerging Th1 effector cells couldmigrate to endothelial wall and undergo “re-activation” after interactingwith antigen-presenting cells (APCs), such asmac-
rophages or dendritic cells, both of which process and present local antigens including oxLDL. Th1 produce inﬂammatory cytokines including IFNγ and TNFα (8) and express CD40 ligand
(CD40L). (C) Locally (in plaques) macrophages and smooth muscle cells (SMC) produce IL12 and IL18 and they can indirectly affect the development of plaques by promoting Th1-cell
differentiation. IFNγ activates macrophages, thereby releasing proinﬂammatory cytokines, CRP, pro-thrombotic and vasoactive mediators. In addition, IFNγ inhibits EC proliferation, in-
duces vascular SMC proliferation and collagen production. During early steps of atherogenesis, when innate immune response is prevalent, the M2 (9) macrophage phenotype predom-
inates. (10) The transition to a M1 phenotype might depend upon the type of the adaptive immune response. Th1 lymphocytes promote the M1 phenotype. (D) Atherosclerotic plaques
have a complex organization from cellular (11) and molecular point of view, consisting of twomain structures: a lipid core (12) and debris from dead cells and a surrounding ﬁbrous cap
consisting of SMC, collagen ﬁbers and immune cells. Decreasing collagen content of the ﬁbrous capmight reduce the stability of the plaque and produce eventually its rupture. ChRc: che-
mokine receptor. SEL: selectin.
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link between PsAand atherosclerosis. Compiled data show that untreated
PsA inﬂammation could produce damage to the CV system even before
it affects the joints [39], and suggests that the measurement of
inﬂammatory-related markers may enhance CV risk evaluation. Current
evidence suggests that the pathway of inﬂammation in atherosclerosis
culminates in altered concentrations of various markers in peripheral
blood, including oxidative stressmolecules [48,49] andmarkers of vascu-
lar inﬂammation like CRP [49], IL-6, ICAM-1 and MCP-1 [50].
4.1.1.1. Tumor necrosis factor-α. The pleiotropic cytokine TNF-α is
among the most potent mediators of inﬂammation. Circulating T lym-
phocytes and monocyte-derived macrophages isolated from PsA pa-
tients produce increased amounts of TNF-α in comparison with
macrophages isolated from healthy controls [8]. Furthermore, levels of
TNF-α in PsA patients are elevated in the synovial tissue and skin le-
sions and correlate with disease activity. TNF-α mediates several ef-
fects, including increased CV risk. Studies in animal models and
humans provide compelling evidence identifying TNF-α as one of sev-
eral regulators of vascular homoeostasis [32]. Among its proatherogenic
effects, TNF-α may induce lipid abnormalities, including high LDL-
cholesterol and low HDL-cholesterol [51]. TNF-αmay also promote hy-
percoagulable state via induction of cell surface expression of tissue fac-
tor (TF) on the endothelial wall and suppress anticoagulant activity via
the thrombomodulin-activated protein C system [52]. The majority of
epidermal T cells in Ps vulgaris lesions can produce type 1 cytokines(IFN-γ, IL-2, and TNF-α). CTL and Th1 effector lymphocyte populations
are also measured in circulating blood in psoriatic patients [53]. TNF-α
also induces endothelial dysfunction including low nitric oxide avail-
ability and up-regulation of endothelial adhesion molecules such as
VCAM-1 [54,55], a critical early step in atherogenesis.
On other hand, TNF-α blockade leads to a signiﬁcant decrease in the
levels of lipoprotein a (Lpa) homocysteine and an increase in apolipo-
protein A-I (Apo A-I), triglyceride and Apo-B concentration. Long-term
use of TNF-α blocking agents interferes with TNF-α function reducing
the high incidence of cardiovascular events and associated vascular
complications in CVdiseases [56]. Taken together, the above-mentioned
studies conﬁrm a critical role for TNF-α in altering a number of well-
studied putative vascular, thrombotic and metabolic risk parameters
(lipids and lipoproteins).
4.1.1.2. Interleukin-6. As an inﬂammatory cytokine, IL-6 regulates
chemokine-directed leukocyte trafﬁcking anddirects transition from in-
nate to adaptive immunity through the regulation of leukocyte activa-
tion, differentiation, and proliferation [57]. During acute and chronic
inﬂammatory response, macrophages release TNF-α in the presence of
a great variety of stimuli, including atherogenic and poorly character-
ized arthritogenic factors. TNF-α action onmacrophages triggers the re-
lease of more TNF-α and IL1-β, which stimulate endothelial cells to
produce IL-6 and IL-8.
IL-6 and their signaling events contribute to both atherosclerotic
plaque development and destabilization [58]. Increased and sustained
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including CRP levels, a widely accepted CVR factor [59]. IL-6 may also
contribute to atherosclerosis and arterial thrombosis by activating the
production of tissue factor, ﬁbrinogen and factor VIII; increasing endo-
thelial cell adhesiveness and stimulating platelet production and aggre-
gation [60]. In addition, IL-6 is produced by smooth muscle cells (SMC)
of many blood vessels and by adipocytes, and, together with CRP, and
TNF-α, is involved in the pathophysiology of metabolic syndrome and
insulin resistance [61].
IL-6-gene polymorphisms were found to correlate with the severity
of coronary artery disease and the risk of MI [62], but not with carotid
atherosclerosis, which seems to be independent [63,64]. Large-scale
human genetic studies are consistent with a causal association between
IL-6 R-related pathways and coronary heart disease [65]. These ﬁndings
clearly suggest a strong association between IL-6 levels and atheroscle-
rosis, MI risk and cardiovascular mortality [66]. In addition IL-6 locally
produced in the endothelium and in SMC is an important autocrine
and paracrine regulator of SMC proliferation and migration. IL-6 de-
creases cardiac contractility via a nitric oxide (NO)-dependent pathway
activating STAT3-dependent anti-inﬂammatory signal transduction.
With regards to SMC, some authors have described a shift from
STAT3-dependent anti-inﬂammatory signaling pathway to STAT-1 pro-
inﬂammatory signaling pathway when IFN-γ and TLR-4 signaling path-
ways are activated [67].
Numerous studies show a strong association between IL-6 and joint
immune-mediated diseases. In the joint, macrophages and mast cells
trigger a proinﬂammatory cascade in the presence of unknown stimuli,
releasing great amounts of TNF-α, which induce the expression of IL-1
and IL-6.Mice deﬁcient inmast cells are comparatively resistant in exper-
imentally induced arthritis. In addition, it is a major promoter of bone re-
sorption in pathological conditions. In particular, IL-6 has a pivotal role in
synovitis, bone erosion and in the systemic features of inﬂammation [68].
In Ps,most available evidence indicates that the pathogenic action of
IL-6 is important. In fact, IL-6 co-localizeswith CD45+perivascular cells
within lesional tissue and reverses the suppressive function of human T
regulatory cells [69].
The successful treatment of certain autoimmune conditionswith the
humanized antibody anti-IL-6 receptor (IL-6R) (Tocilizumb) has em-
phasized the clinical importance of cytokines that signal through the
β-receptor subunit glycoprotein 130 [70].
IL-6 may, in both cardiovascular and joint-diseases involving Th1/
Th17 mechanisms, alter the balance between the effector and regulato-
ry arms of the immune system and drive a proinﬂammatory phenotype
reinforcing innate and adaptive immune-mediated positive feedback. In
addition, IL-6 combined with transforming growth factor beta (TGF-β)
promotes the differentiation of IL-17-secreting Th17-cells [71], potenti-
ating the immune effector mechanism. In both pathologies, arterial dis-
ease and Ps/PsA, IL-6 seems to be a critical mediator of long-term
chronic inﬂammation and to have deleterious effect in the arterial
wall and in the joint.
4.1.1.3. Endothelin-1. The family of endothelins (ET) includes three 21-
aminoacid isoforms endothelin-1 (ET-1), endothelin-2 (ET-2) and
endothelin-3 (ET-3), which have endogenous pressor activity and are
secreted by different tissues and cells. In addition, ET-1 is a vasoactive
peptide that induces vasoconstriction, inﬂammation, ﬁbrosis and has
mitogenic potential for SMC [72]. In the skin, ET-1 participates in
keratinocyte proliferation, neoangiogenesis and chemotaxis. Its levels
are elevated in psoriatic lesions and serum of patients with Ps [73]. Sy-
novial tissue and serumof patientswith PsA all show strongly enhanced
ET-1 receptor expression [74].
4.1.1.4. C-reactive protein. A considerable amount of evidence implicates
CRP as a predictive marker for future CV events and mortality in differ-
ent settings, particularly under metabolic syndrome conditions in the
general population [75,76]; CRP has also been implicated as a directpartaker [77,7,78]. CRP stimulation of the production of plaque-
destabilizingMMPs andMCP-1, a decrease in the activity of endothelial
nitric oxide synthase (eNOS) and an impairment in endothelium-
dependent vasodilation can be mentioned among the most prominent
ﬁndings [79]. In vitro studies provide evidence for direct proatherogenic
effects of CRP, including increased endothelial dysfunction [80]. Baseline
CRP levels were elevated in patients with Ps with and without psoriatic
arthritis and Etanercept, a biologic TNF antagonist, treatment may re-
duce CRP levels in both groups [81].
4.1.1.5. Adipokines. Interestingly, in metabolic disorders associated
with Ps/PsA, inﬂamed adipose tissue may enhance inﬂammatory
proatherogenic status via adipokine production (leptin, adiponectin,
and resistin) and cytokine (TNF-α and IL-6) secretion. Adipose tissue
inﬂuences both natural and adaptive immunity and links inﬂammation,
metabolic dysfunction and cardiovascular disease [82].
4.1.1.6. Matrix metalloproteinases (MMPs). MMPs are endoproteases
with collagenase and/or gelatinase activity which exert deleterious
effects on the endothelium integrity and collagen ﬁbers, promoting ath-
erosclerotic plaque destabilization and accelerating the process of ath-
erothrombosis [83,84]. MMP-1 serum levels and gene expression are
elevated in PsA [85].
4.1.2. Adaptive immunity
As previously mentioned, Ps/PsA and atherosclerosis share certain
common underlying pathogenic inﬂammatory mechanisms. Speciﬁcal-
ly, both are associatedwith Th1 and CTL (cytotoxic T lymphocyte) effec-
tor cell-mediated events in vivo [57], and are elevated in circulating
blood [53]. In contrast, the T regulatory activity is reduced.
4.1.2.1. Cellular immune response. Myeloid dendritic cells (mDCs) can
stimulate both memory and naive T cells, and are the most potent of
all the antigen-presenting cells in normal and various pathophysiologi-
cal conditions. In turn, activated T cells undergo ﬁrm adhesion and
transendothelial migration to inﬂammatory focus. Extravasation is
orchestrated by the combined action of cellular adhesion receptors
and chemotactic factors. Adhesion molecules are therefore particularly
implicated in a wide variety of cardiovascular and autoimmune disor-
ders that involve inﬂammation.
The development and maintenance of psoriatic plaque are depen-
dent on the participation of inﬁltrating T lymphocytes (CD4, CD8) and
local antigen-presenting cells (APCs) (Langerhans cells, myeloid and
plasmacytoid-DC). DCs are increased in psoriatic lesions and are critical-
ly involved in the induction of Th1 and Th17 cell proliferation, which, in
turn, release IFN-γ and IL-17, respectively. Activated mDCs produce IL-
23 [86] and TNF-α. IL-23 stimulates the secretion of IL-22 by Th17
cells, which may be involved in epidermal hyperplasia [5].
The effects of IL-17A-producing T helper 17 (Th17) cells include
suppressive effects of T regulatory (Treg) subsets, which have also
been implicated in both pathologies. The association of IL-17A with Ps
and PsA has been extensively described [87] and a growing body of
evidence suggests that IL-17A might also be involved in atherosclerosis
[88].
IL-17 seems to have amodulatory role in atherosclerosis, but studies
available show contrasting results, which could be attributed to differ-
ent approaches and models. IFN-γ and IL-17 serum levels are increased
in patients with coronary artery disease but are undetectable in healthy
volunteers. Coronary syndrome correlates with increased IL-17 levels as
well as high-sensitivity CRP and IL-6, both of which predict MI risk [89].
In addition, TNF-α and IL-17 synergistically up-regulate further cyto-
kine transcription in both diseases, Ps and atherogenesis [90].
These observations make IL-17A an interesting therapeutic target
to modulate both PsA/Ps disease activity as well atherosclerosis/cardio-
vascular risk. Obesity may play an important role by amplifying the in-
ﬂammation of arthritis through the Th1/Th17 response [91].
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with inﬂiximab, with moderate to severe plaque Ps, led to decreases
in clinical disease scores and circulating levels of Th17, Th1 cells and as-
sociated TNF-α release [92].
T cell activation is under control from T-regulatory immune cell
(Treg) activity via IL-10 and TGF-β [93,94]. Treg lymphocytes are char-
acterized by expression of TGF-β, a T cell suppressive cytokine [95].
Reduced numbers and/or activity of Treg cells may produce hyperactiv-
ity of Th1 ⁄Th17 subsets in both pathologies [96–98]. Ps and coronary
artery disease patients show impaired inhibitory function of Treg [99,
100]. Serum and epidermal levels [93,94] of TGF-β in Ps patients are
associated with Ps disease severity [101,102] and are diminished in
low Ps [5]. In atherosclerosis, high serum levels of TGF-β and IL-10
may inhibit plaque formation [103,104]. In addition, TGF-β promotes
plaque stabilization. Taken together protective effect of TGF-β is due
to its inhibition of T cells. Of note, substance P (SP), the prototype
tachykinin peptide, displays Nuclear Factor-Kappa β (Nf-κβ)-depen-
dent proinﬂammatory effects, which are silenced by IL-10 and TGF-β
in T lymphocytes and macrophages, respectively [105].
4.1.2.2. Humoral immune response. Not all immune responses that
mounted during the course of atherosclerosis are pathogenic. Humoral
response seems to protect rather than harm the host. Several lines of
evidence support the hypothesis that humoral immunity protects
patients against atherosclerosis. First, the injection of immunoglobulin
preparations inhibits atherosclerosis. Second, spleen removal (a B-cell-
rich lymphoid organ) seems to deteriorate vascular disease condition.
Third, oxidized LDL plus adjuvant immunization promote athero-
protection [2]. Although the underlying mediating mechanism of this
effect remains poorly understood, most evidence so far indicates that
athero-protection is due to a T cell dependent B-cell-mediated mecha-
nism, probably involving antibody dependent clearance of LDL and T
cell-mediated inhibition of vascular inﬂammation or humoral depen-
dent regulation [15]. This atheroprotective response must be conﬁrmed
in humans.
4.2. Non-inﬂammatory risk factors
Ps, PsA and atherosclerosis share derangements in different meta-
bolic pathways involving insulin-dependent diabetes mellitus (IDDM),
dyslipidemia, hypertension, obesity, and mostly metabolic syndrome,
which may be related to an increase in the prevalence of CVD. Ps/PsA
derangements mentioned above may act due to their capability of in-
ducing inﬂammation on the endothelial lining to initiate the process
of atherosclerosis. So far, no pathophysiological mechanism for this as-
sociation has been identiﬁed [52].
4.2.1. Hypertension
Several studies have found an increase in the prevalence of hyper-
tension in Ps patients, although the deﬁnition of hypertension is very
heterogeneous among these studies. Themajority of these papers estab-
lish a relationship between the severity of Ps and the risk of hyperten-
sion [106–108]. Other authors have not observed a signiﬁcant
association between Ps and hypertension [109].
4.2.2. Diabetes mellitus
IDDM is responsible for metabolic alterations, accompanied by
chronic inﬂammation and endothelium dysfunction. Observational
studies show that the risk of IDDM is higher in patients with Ps com-
paredwith a healthy control group. This risk increaseswith the duration
and severity of Ps and it is not related to a high body mass index (BMI)
alone. In a case-control study from Israel, the risk of diabetes was signif-
icantly higher in individuals with Ps [110]. Similarly, PsA patients have a
higher prevalence of IDDM, even after adjusting for the BMI [111]. TNFα
antagonist therapy in patients with Ps seems to improve insulin sensi-
tivity in limited preliminary data [112]. Finally, a few isolated cases ofPs patients with diabetes develop unpredictable hyperglycemia after
starting treatment with TNF-α inhibitors [113].
4.2.3. Obesity
Recent studies have shown that obesity may precede the onset of Ps
as a risk factor [114], whereas a higher BMI is associated with more se-
vere skin disease activity [26]. The inﬂuence of obesity on psoriatic dis-
eases is the result of complex interactions of inﬂammatory and
metabolic factors. The proinﬂammatory cytokines stimulate adipocytes
to synthesize neuropeptides and more cytokines, which are critical in
the pathogenesis of the psoriatic and CVD [52]. Some studies have
shown that the use of anti-TNF-α drugs is associated with signiﬁcant
weight gain and BMI increase in Ps and PsA patients [124].
4.2.4. Smoking
Heavy and long-term smoking [125] have been associated with in-
creased Ps risk in both men and women [126], particularly pustular Ps
[116,117,118]. Smoking increases oxidative damage, promotes inﬂam-
matory changes and enhances Ps-associated gene expression [119]
and CVR [50,120].
4.2.5. Dyslipidemia
Ps patients have a higher prevalence of dyslipidemia and triglycer-
ides and lower prevalence of HDL levels. However, associations with
total cholesterol and LDL have not been found statistically signiﬁcant
in a multivariate analysis study [121].
Several cross-sectional studies using varying populations and ana-
lytic approaches have found an association between Ps and an increased
risk of hyperlipidemia [122,123]. Studies regarding the effects of TNF
antagonists on blood lipids have shown mixed and unclear results.
4.2.6. Metabolic syndrome
Themetabolic syndrome consists of a constellation of clinical features
involving abdominal obesity (waist circumference N 94 cm in men
and N 80 cm in women), and two or more of the following clinical situa-
tions: HDL b 40 mg/dl in men and 50 mg/dl in women, TG N 150 mg/dl,
fasting blood glucose N 100 mg/dl, blood pressure N 130/85 mm Hg or
treatment for hypertension. The metabolic syndrome is character-
ized by increases in the immunological activity of Th1, which sug-
gests it may be associated with Ps because of shared inﬂammatory
pathways.
Gisondi et al. 2008 reported that, among Ps patientswithout system-
ic medication, forty-year-old and older people have a higher prevalence
of metabolic syndrome. This association is independent from the sever-
ity of Ps but directly related to its duration [124].
Recently, Raychaudhuri et al. observed an increased prevalence of
metabolic syndrome in patients with PsA; among these patients, 24.6%
had coronary artery disease and 39.3% DM type 2 [52]. Patients with
metabolic syndromeand PsAhave an increased risk for CVD andmortal-
ity [125–129].
On the other hand, serum uric acid exerts its inﬂuence by condition-
ing the association of Ps with metabolic syndrome [130]. High serum
uric acid levels correlate with an increased risk of carotid IMT or with
the presence of carotid plaques. The study of a ﬁfty-three -PsA-patient
cohort, without CVR factors or clinically evident CVD, has shown a sig-
niﬁcant correlation between carotid IMT and serumuric acid concentra-
tion. Taken together, asymptomatic hyperuricemic PsA patients have
been associated with subclinical atherosclerosis [131].
5. Common angiogenic factors for Ps and atherosclerosis
Angiogenesis appears to be pathological in some chronic inﬂamma-
tory diseases, like Ps and RA. It is possible for reactive homeostatic or
pathological angiogenesis to play an important role in atherosclerosis.
Serum levels of proangiogenic cytokines and growth factors have
been shown to be signiﬁcantly elevated in Ps patients compared to
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angiogenesis-inducing factors, including VEGF, hypoxia-induced
factor-1 (HIF-1), TGF-β, TNF-α, IL-8 and IL-17.
Some recent reports [133] have demonstrated that VEGF overex-
pression in serum and skin biopsies of Ps patients has a key role in the
pathogenesis of Ps. VEGF exerts an early and late cardiovascular effect.
In fact, it primes endothelial cells to overexpress E-selectin, an adhesion
molecule necessary for transepithelial migration of leukocytes [134,
135], leading to the enrichment of immune cells into the intima at var-
ious stages of atherogenesis.
6. Oxidative mechanisms common to atherosclerosis and Ps
Cellular dysregulation and damage [47] could be the result of over-
production or insufﬁcient removal of ROS. In the skin, ROS can be gen-
erated either endogenous or exogenously. Endogenously, ROS are
produced through the electron transport chain and enzymes such as
cyclooxygenases (COX) [136], lipoxygenases [137], NADPH oxidases
[138] and myeloperoxidases [139]. Exogenous sources that trigger
ROS production include UV radiation and heavy metals [47]. In Ps,
antioxidant defense mechanisms seem to be impaired, including
superoxide dismutases (SODs), glutathione peroxidases, glutathione
reductase, catalase, thioredoxin/thioredoxin reductase system and
metallothioneins. Augmented ROS production in the skin leads to
downstream molecular events that promote atherosclerosis [47,140,
141].
The antioxidant activity of vitamin D is well known/widely charac-
terized. The knowledge of nonclassical functions emerges from studies
that indicate a close association between a low vitamin D status and in-
creased risk of IMID and CVD [142].
It is also known that vitamin D insufﬁciency induces metabolic,
procoagulant and inﬂammatory perturbations. Recent studies indicate
that it also increases the risk of MI by promoting established CVR
factor-mediated mechanisms that predispose to atherothrombosis
[143].
Immunomodulatory role of vitamin D in human health implicates
appropriate signaling for both innate immune responses (antimicrobial
activity and antigen presentation) and adaptive immune responses
(T and B lymphocyte function) [144, 145,146].
Recent data indicate that vitamin D analog calcipotriol interferes
with the Th17 cytokine-induced proinﬂammatory antimicrobial
peptides (psoriasin and koebnerisin), which are released from
keratinocytes present in psoriatic skin and act as chemoattractant and
“danger signals” to amplify inﬂammation in Ps [147]. In addition,
in vitro studies indicate that distinct DC subsets are differentially pro-
grammed by vitamin D, promoting the development of different types
of Treg cells [148].
7. Lessons from CVD and rheumatic associated therapies
Whether antirheumatic therapies increase or decrease CV risk is
controversial. Glucocorticoids (GCs) are known to cause hypercholes-
terolemia, hypertriglyceridemia, weight gain, hypertension and glucose
intolerance, all factors promoting CVD. However, GCs are not ever con-
ﬂicting. In RA patientswith a knownhistory of CVD, steroid therapy sur-
prisingly attenuated the risk of CV death [149]. The mechanism of this
apparent discrepancy with GC exposure is still unknown, but it seems
to be related with dose, duration and intensity of the exposure.
Although coronary artery disease and acute myocardial infarction
are inﬂammatory disorders, the only drugs with anti-inﬂammatory ef-
fect so far widely used in ischemic heart disease are aspirin and statins.
The contribution of coxibs and most nonsteroidal anti-inﬂammatory
drugs (NSAIDs) to lowering CVR is not well established and the evi-
dence available so far is controversial.
Multiple studies provide evidence that methotrexate is protective
against CV events and CV mortality, although the protective beneﬁt isunder discussion [143]. Immunomodulatory or immunosuppressive
therapies, such as cyclosporine and colchicine,may have beneﬁts in cor-
onary artery disease. Other studies have found that glucocorticoids plus
cytotoxic immunosuppressive agents (azathioprine, cyclosporine, and
leﬂunomide) are associated with an increased amount of CV events
when compared with methotrexate alone [150].
The new targeted biological therapies, such as the suppression of
systemic inﬂammation by anti-TNF therapies, seem to be associated
with concomitant reduction in the risk of CV events [151], although
the effect of TNF-α antagonists in lowering proatherogenic status
needs further investigation.
In addition, cardiovascular therapy drugs could change the proinﬂam-
matory status of PsA patients under treatment with 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (statins), angiotensin-
converting-enzyme (ACE) inhibitors and/or angiotensin II receptor an-
tagonists (AT-II blockers). Hence, their prescription should be managed
cautiously, especially for patients with a documented CV disease or in
the presence of CV risk factors.
Other drugswith potential beneﬁtsmay include the thiazolidinedione
(TZD) family, which produces positive effects on both CVR factors and Ps.
Targeted therapeutic interventions alongwith an effective control of
the inﬂammation may have more beneﬁcial CV effects than direct CV
toxicity. There is a need for more studies addressing the role of current
biological therapies on patients with a CV risk proﬁle [22].8. The central role of the immune system
Atherosclerosis is a complex disease but, as speciﬁc knowledge in-
creases, the immune system can be clearly recognized to be involved
in all steps of vascular pathology. Both classical and nonclassical CVR
factors are closely interconnected in the production of chronic inﬂam-
mation through loss of immune homeostasis; indeed, either molecules
or cells involved in atherogenesis present altered regulatory and/or ef-
fector immune functions, attenuating and promoting atherogenesis.
Some authors have proposed an autoimmune origin in atherosclerosis
[76,77]. Immune system homeostasis alterations against the patient's
own antigens and the increasing prevalence of atherosclerosis in
immune-mediated diseases such as diabetes, periodontal disease,
systemic sclerosis, antiphospholipid syndrome, RA, SLE, ankylosing
spondylitis (AS) and PsA strongly reinforce the involvement of autoim-
mune mediators and the key role of inﬂammation in atherosclerosis
[152]. This autoimmune response to oxidized LDL is a driving force for
T cell activation in the human atherosclerotic plaque [153]. The fact
that low and high grade chronic inﬂammatory disorders present an ac-
celerated progression of atherosclerosis constitutes indirect but critical
evidence that strengthens the above-mentioned immune-mediated
driven inﬂammation.
The Ps/PsA proatherosclerotic proﬁle seems to be related to chronic
inﬂammation through classical and non classical factors. Important in-
sights reviewed in this article indicate that most, if not all inﬂammatory
factors, are the result of immune activation and cytokine-driven inﬂam-
mation. For example, Th1, CTL and Th17 effector cells are the dominant
types in the pathogenesis of the psoriatic and cardiovascular diseases
and are the most abundant T lymphocytes in skin, joints and human
atherosclerotic plaque [57]. In addition, reduced levels of circulating
anti-inﬂammatorymediators and Treg,may increase CV risk in both dis-
eases [154]. According to its common inﬂammatory cytokine proﬁle,
TNF-α levels are elevated in patients with Ps, PsA and CVD and exerts
its powerful proinﬂammatory pathogenic inﬂuence in multiple ways,
including activation of endothelial and immune cells status [155] induc-
ing up-regulation of adhesion molecules [156] and promoting a more
procoagulant [157] and vasoconstrictor phenotype [158]. This cytokine
might be therapeutically antagonized with anti-TNF (Etanercept) lead-
ing to a chronic Th2 cytokine proﬁle that could be beneﬁcial for the at-
tenuation of Ps development and atherogenesis. Although anti-
1 They were deﬁned in the text at ﬁrst use.
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tion must be conﬁrmed [2].
Indirect evidence indicating that immune-mediated inﬂammation is
a key regulator in the crossroad of pathogenesis between Ps/PsA and
atherogenesis derives from the role of certain therapies. Some drugs
used in the treatment of CV disease, such as statins and ACE-
inhibitors, have anti-inﬂammatory activity. In addition, systemic treat-
ments for Ps that decrease inﬂammation also reduce CV risk. [159]. Fur-
ther evidence that accounts for the prevailing immune-mediated
mechanism in inﬂammation status derives from the fact that TLRs are
the best candidates to explain what triggers and sustains the natural
and adaptive immune response, maintaining proinﬂammatory cytokine
gene expression in chronic inﬂammation. Proinﬂammatory TLR-2 and
TLR-4 worsen atherosclerosis [160] in general population, in Ps and
PsA patients.
Finally, the role of obesity, metabolic syndrome (possible via
hypertriglyceridemia and associated abdominal adiposity in Ps/PsA
patients) and probably DM, in this scenario of severe Ps and accelerated
CVR, emerges usually from the concept that adipose tissue is just an
“endocrine organ”. Now we know adipocytes express TLRs, which are
involved in the innate immune response reacting to exogenous and
endogenous stimuli by releasing inﬂammatory cytokines, adipokines
and other key mediators of Ps and atherogenesis, including IL-6, TNF-
α, leptin, adiponectin, resistin and PAI-1. In addition, a consistent
association was described between increasing obesity and lower
serum 25-hydroxy vitamin D (25D) concentrations [161]. Because the
immunomodulatory action of vitamin D is required for appropriate
immune function, the balance of Th17 and Treg activity can be altered
[149].
Pathogenic immune cells proﬁle and proinﬂammatory circulating
factors common to Ps/PsA and atherosclerosis, like deleterious immune
cell types, proatherogenic cytokine and chemokine levels, enhanced
acute-phase proteins, up-regulated vascular adhesionmolecule expres-
sion, increased proteases, augmented ROS release, adipokines, activated
innate receptors, increased vasoactive molecules, obesity-associated
vitamin D depletion, altered thrombosis factor balance and increased
proangiogenic factors should be critical in the pathological outcome of
atherosclerosis.
In summary, chronic immune-mediated inﬂammation plays a key
role in the pathogenesis of atherosclerosis in Ps, acting independently
and/or synergistically with the conventional risk factors. Therefore, it
makes sense for the Framingham risk score (FRS), which only takes
into account traditional CV risk factors for estimating the 10-year risk
of CV events, to consider factors related to Ps-comorbidities like meta-
bolic syndrome and diabetes, butmay underestimate CVR related to un-
derlying inﬂammatory factors associated with this disease, also known
as non-traditional risk factors. CRP has been shown to enhance the pre-
dictive value of FRS forMI and CVdeath in normal populations, although
there is no way so far to perform a valid quantiﬁcation of additional CV
risk in PsA through CRP.
Improvement by inﬂammatory suppression argues strongly for im-
mune-mediated inﬂammation as the central risk factor for CVD in PsA
However, many of the studies investigating mechanisms of PsA associ-
ated with atherogenesis are not deﬁnitive or conclusive enough. Larger,
more systematic and controlled studies are needed to conﬁrm many of
the ﬁndings previously reviewed.
9. Conclusions
Most evidence reviewed in this article strongly support the hypoth-
esis that the inﬂammatory immune-mediated could be involved in the
pathogenesis of the atherogenesis, from its initiation to plaque forma-
tion, rupture and associated thrombotic complications. Taken together,
evidence so far strongly suggests immune-mediated inﬂammation is
the central actor in atherogenesis beyond all risk factors, regardless of
whether they are “traditional” or “non-traditional”. Although certaincrossroads between immune-mediated inﬂammation pathways are ac-
tivated in general population under cardiovascular risk conditions, it
seems to be potentiated in psoriasis patients and other IMID. This is in
agreement with accumulated evidence so far that indicates an en-
hanced CVR associated with Ps via both, traditional and non-
traditional factor immune-modulation.
Although administration of non-selective immunosuppressive drugs
will probably not be useful for treatment of idiopathic atherosclerosis, it
must be evaluated in the context of an aggressive clinical presentation
of Ps since the balance between potential toxicities and beneﬁts is not
the same in the two groups. Evidence so far suggests that patients
with PsA should be treated more aggressively for CVR prevention and
modiﬁcation. Therefore, selective long-term anti-atherosclerotic
immunomodulation-oriented therapy might improve atherogenesis in
both general population and Ps patients.
The existence of proatherogenic immunological pathways in CID
that could damage the CV system reveals potential targets for more ef-
ﬁcient therapies. Taking into account that Ps and PsA activate the
proatherogenic immune-mediated inﬂammatory response associated
with both “traditional” and “non-traditional” CVR factors, it seems pos-
sible that future drug development in atherosclerosis in Ps/PsA-related
therapy should change from the currently dominating biologic agents
to more speciﬁc molecular immune mediators implicated in
immunopathogenesis. This much more selective therapy requires
long-term studies until it is available and accurate enough.
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